Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer.
暂无分享,去创建一个
Fan Wang | Shuang Liu | Zhaofei Liu | Hui-yun Zhao | Jiyun Shi | Bing Jia | Zilin Yu | Zhi Yang | Zhengjie He
[1] Shuang Liu,et al. Coligand effects on the solution stability, biodistribution and metabolism of the (99m)Tc-labeled cyclic RGDfK tetramer. , 2008, Nuclear medicine and biology.
[2] Young-Seung Kim,et al. Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .
[3] W. Oyen,et al. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. , 2007, Nuclear medicine and biology.
[4] R. Sachleben,et al. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents. , 2007, Bioconjugate chemistry.
[5] M. Walter,et al. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. , 2007, Bioconjugate chemistry.
[6] W. Oyen,et al. Improved targeting of the αvβ3 integrin by multimerisation of RGD peptides , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[7] Shuang Liu,et al. Impact of PKM linkers on biodistribution characteristics of the 99mTc-labeled cyclic RGDfK dimer. , 2006, Bioconjugate chemistry.
[8] P. Yalamanchili,et al. Structure-activity relationships of 111In- and 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. , 2006, Bioconjugate chemistry.
[9] Shuang Liu. Radiolabeled Multimeric Cyclic RGD Peptides as Integrin αvβ3 Targeted Radiotracers for Tumor Imaging , 2006 .
[10] Bing Jia,et al. 99mTc-Labeled Cyclic RGDfK Dimer: Initial Evaluation for SPECT Imaging of Glioma Integrin αvβ3 Expression , 2006 .
[11] S. Gambhir,et al. Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2 , 2006 .
[12] S. Mohammed,et al. Effect of coligands on biodistribution characteristics of ternary ligand 99mTc complexes of a HYNIC-conjugated cyclic RGDfK dimer. , 2005, Bioconjugate chemistry.
[13] S. Gambhir,et al. microPET Imaging of Glioma Integrin αvβ3 Expression Using 64Cu-Labeled Tetrameric RGD Peptide , 2005 .
[14] M. Schwaiger,et al. Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[15] Horst Kessler,et al. Noninvasive Visualization of the Activated αvβ3 Integrin in Cancer Patients by Positron Emission Tomography and [18F]Galacto-RGD , 2005, PLoS medicine.
[16] S. Robinson,et al. Radiolabeled Integrin αvβ3 Antagonists as Radiopharmaceuticals for Tumor Radiotherapy , 2005 .
[17] Hans-Jü Rgen Wester. Molecular Targeting with Peptides or Peptide-Polymer Conjugates: Just a Question of Size? , 2005 .
[18] Ryan Park,et al. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[19] W. Oyen,et al. Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. , 2004, Cancer biotherapy & radiopharmaceuticals.
[20] R. Haubner,et al. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. , 2004, Current pharmaceutical design.
[21] H. Jin,et al. Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.
[22] I. Pastan,et al. Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA) , 1994, European Journal of Nuclear Medicine.
[23] M. Schwaiger,et al. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation , 2004 .
[24] M. Schwaiger,et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. , 2004, Bioconjugate chemistry.
[25] Ryan Park,et al. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.
[26] J. Bading,et al. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. , 2004, Nuclear medicine and biology.
[27] Peter S. Conti,et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[28] J. Folkman,et al. Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.
[29] M. Schwaiger,et al. Radiotracer-based strategies to image angiogenesis. , 2003, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[30] S. Robinson,et al. Design, synthesis, and evaluation of radiolabeled integrin αvβ3 receptor antagonists for tumor imaging and radiotherapy , 2003 .
[31] Horst Kessler,et al. Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. , 2003, Chemistry.
[32] L. Knight,et al. Radiopharmaceuticals for targeting the angiogenesis marker αvβ3 , 2003 .
[33] S. Robinson,et al. Integrin alphavbeta3 directed radiopharmaceuticals for tumor imaging , 2003 .
[34] Milind Rajopadhye,et al. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.
[35] Manfred Schwab,et al. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. , 2002, Cancer research.
[36] W. Oyen,et al. Tumor Targeting with Radiolabeled v 3 Integrin Binding Peptides in a Nude Mouse Model , 2002 .
[37] S. Liu,et al. Synthesis and characterization of two (111)In-labeled DTPA-peptide conjugates. , 2001, Bioconjugate chemistry.
[38] M. Rajopadhye,et al. (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. , 2001, Bioconjugate chemistry.
[39] J. Barrett,et al. 99mTc-labeling of a hydrazinonicotinamide-conjugated vitronectin receptor antagonist useful for imaging tumors. , 2001, Bioconjugate chemistry.
[40] M Schwaiger,et al. Tumor angiogenesis targeting using imaging agents. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.
[41] Sibylle Ziegler,et al. Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .
[42] M Schwaiger,et al. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[43] M. Rajopadhye,et al. Isomerism and solution dynamics of (90)Y-labeled DTPA--biomolecule conjugates. , 2001, Bioconjugate chemistry.
[44] Shuang Liu,et al. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. , 2001, Bioconjugate chemistry.
[45] Horst Kessler,et al. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting , 1999 .
[46] T. Waldmann,et al. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[47] S. Mirzadeh,et al. Physical parameters and biological stability of yttrium(III) diethylenetriaminepentaacetic acid derivative conjugates. , 1998, Journal of medicinal chemistry.
[48] L. Jennings,et al. Integrin-mediated signal transduction , 1998, Cellular and Molecular Life Sciences CMLS.
[49] P. Smith-Jones,et al. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours. , 1998, Nuclear medicine and biology.
[50] R L Juliano,et al. Integrin signaling and cell growth control. , 1998, Current opinion in cell biology.
[51] E P Krenning,et al. Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. , 1998, Nuclear medicine communications.
[52] I. Pastan,et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.